We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
  • SKIP TO CONTENT
  • SKIP NAVIGATION
  • Drug & Device Products
    • FDAnews Books Library
    • Events
    • Form 483s Database
    • Publications
    • Webinar Training Pass
    • eCFR and Guidances
    • Books
  • Clinical Products
  • Advertising
  • White Papers
  • Contact Us
  • About Us
  • COVID-19
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » TEVA'S COPAZONE SHOWS EFFICACY IN RRMS STUDY

TEVA'S COPAZONE SHOWS EFFICACY IN RRMS STUDY

May 10, 2006

Data from a 10-year study showed that 92 percent of relapsing-remitting multiple sclerosis (RRMS) patients who remained on Teva's Copaxone (glatiramer acetate injection) were still walking without assistance despite an average disease duration of more than 15 years. The study was published in the journal Multiple Sclerosis.

The study, which was conducted in 251 RRMS patients, began in 1991 as a double-blind, placebo-controlled trial in which patients were randomized to receive either 20 mg of Copaxone or placebo by subcutaneous injection daily for a mean of 30 months. A total of 232 patients (125 on Copaxone and 107 placebo, the modified intent-to-treat cohort) were evaluated.

Investigators looked at the percentage of patients who progressed to Kurtzke Expanded Disability Status Scale (EDSS) 4, at which they were still ambulatory despite moderately severe disability; to EDSS 6, at which a cane, crutch or brace is required for mobility; and to EDSS 8, in which patients were wheelchair-bound. At the start of treatment, patients had an average EDSS score of 2.79. After 10 years, the patient group on Copaxone showed significantly decreased accumulation of disability, with 24 percent of patients reaching EDSS 4, eight percent reaching EDSS 6 and one percent reaching EDSS 8.

"Copaxone provides RRMS patients with a treatment option that has demonstrated long-term efficacy and safety," said Corey Ford, director of the Multiple Sclerosis Specialty Clinic at the University of New Mexico Health Sciences Center and a lead investigator in the trial. "Results of the study are consistent with the presumed mechanism of action of Copaxone, which appear to treat inflammation and neurodegeneration, the underlying pathologies of multiple sclerosis These data [are] clinically useful for the MS community."

KEYWORDS Daily International Pharma Alert

Upcoming Events

  • 08Sep

    Organizing Data and Document Archives: Finding a Needle in a Haystack for FDA Inspections

  • 15Sep

    Califf’s Post-PDUFA, Post-COVID FDA Agenda: Key Developments, Insights and Analysis

  • 20Sep

    Building a World-Class Pharmaceutical Advertising and Promotion Review Program

  • 21Sep

    The FDA’s Focus on Clinical Data Integrity Throughout Product Development and Approval

  • 22Sep

    FDA’s New Quality Management System Regulation: What the Proposed Harmonization with ISO 13485 Means for Devicemakers

  • 11Oct

    1st Annual Quality Management vSummit

Featured Products

  • FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

    FDA’s New Quality System Regulation: Transitioning from QSR to ISO 13485

  • Selecting and Implementing Electronic Document Management Systems in the EU

    Selecting and Implementing Electronic Document Management Systems in the EU

Featured Stories

  • AngioDynamics Gets Expanded Clearance for Auryon Atherectomy System

  • Aura Biosciences Receives Fast Track Designation for Bladder Cancer Candidate

  • FDA Issues Update on Becton Dickinson’s Recall

  • FDA Grants Accelerated Approval to Enhertu for HER2-Mutant NSCLC

The Revised ICH E8: A Guide to New Clinical Trial Requirements

Learn More
  • Drug Products
    • Quality
    • Regulatory Affairs
    • GMPs
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Device Products
    • Quality
    • Regulatory Affairs
    • QSR
    • Inspections and Audits
    • Postmarket Safety
    • Submissions and Approvals
    • Research and Development
    • Commercial Operations
  • Clinical Products
    • Trial Design
    • Data Integrity
    • GCP
    • Inspections and Audits
    • Transparency
  • Privacy Policy
  • Do Not Sell My Personal Information
Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 703.538.7600 – Toll free 888.838.5578

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing